RSS   Newsletter   Contact   Advertise with us
Post Online Media

Mesoblast names Bill Burns as vice chairman

William A. BurnsMesoblast Limited, a regenerative medicine company, appointed William A. Burns, former chief executive officer of Roche Pharmaceuticals, as vice chairman.

Mr. Burns brings to Mesoblast extensive international commercial, business development, and operational experience in the pharmaceutical industry.

From 1991-1998, he was Global Head of Strategic Marketing and Business Development at F. Hoffmann-La Roche Ltd. From 2000-2009, Mr. Burns was a Member of the Corporate Executive Committee of the Roche Group and from 2001-2009, he was CEO of Roche Pharmaceuticals.

During this time, Mr. Burns had significant involvement in the privatisation of Genentech, the integration of Boehringer Mannheim and the negotiations that resulted in Roche becoming a majority owner of Chugai Pharmaceuticals in Japan.

Mr. Burns has been a non-executive Director of Chugai Pharmaceuticals (2001-2014), Genentech (2004-2014), Roche (2010-2014), and Shire Pharmaceuticals plc since 2010, most recently as Senior Independent Non-Executive Director.

His other key appointments in healthcare include roles as Vice Chairman, Vestergaard, Governor and Trustee for Wellcome Trust, Trustee for the Institute of Cancer Research, London, and Scientific Advisory Board Member for the University of Cologne/Bonn Center for Integrated Oncology.


More inside POST

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy